• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SYT-SSX对滑膜肉瘤细胞中细胞周期蛋白D1的表达至关重要:t(X;18)(p11.2;q11.2)易位的功能获得。

SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation.

作者信息

Xie Yuntao, Skytting Björn, Nilsson Gunnar, Gasbarri Alessandra, Haslam Karl, Bartolazzi Armando, Brodin Bertha, Mandahl Nils, Larsson Olle

机构信息

Department of Oncology and Pathology, Karolinska Hospital, SE-171 76 Stockholm, Sweden.

出版信息

Cancer Res. 2002 Jul 1;62(13):3861-7.

PMID:12097301
Abstract

The SYT-SSX fusion gene has been implicated in the malignant tumor cell growth of synovial sarcoma, but the underlying molecular mechanisms are still poorly understood. Here we demonstrate that SYT-SSX is critical for the protein level of cyclin D1 in synovial sarcoma cells. Antisense oligonucleotides to SYT-SSX mRNA rapidly and drastically decreased cyclin D1 and subsequently inhibited cell growth. This effect is specific for SYT-SSX, without involving the wild-type genes SYT or SSX. The decrease in cyclin D1 expression, which occurred shortly after inhibition of SYT-SSX expression, was found to be primarily dependent on an increased degradation of the cyclin D1 protein, as assessed by pulse-chase experiments using [(35)S]methionine. Furthermore, transfection of mouse fibroblasts with SYT-SSX cDNA increased the stability of cyclin D1. Because treatment with a proteasome inhibitor restored cyclin D1 expression, it seems like SYT-SSX interferes with ubiquitin-dependent degradation of cyclin D1. However, SYT-SSX-regulated cyclin D1 expression was proven to be independent of the glycogen synthetase kinase-3beta pathway. Taken together, our study provides evidence that SYT-SSX stabilizes cyclin D1 and is critical for cyclin D1 expression in synovial sarcoma cells. SYT-SSX-dependent expression of cyclin D1 may be an important mechanism in the development and progression of synovial sarcoma and also raises the possibility for targeted therapy.

摘要

SYT-SSX融合基因与滑膜肉瘤的恶性肿瘤细胞生长有关,但其潜在的分子机制仍知之甚少。在此我们证明,SYT-SSX对滑膜肉瘤细胞中细胞周期蛋白D1的蛋白水平至关重要。针对SYT-SSX mRNA的反义寡核苷酸迅速且显著地降低了细胞周期蛋白D1的水平,随后抑制了细胞生长。这种效应是SYT-SSX特有的,不涉及野生型基因SYT或SSX。通过使用[(35)S]甲硫氨酸的脉冲追踪实验评估发现,在抑制SYT-SSX表达后不久发生的细胞周期蛋白D1表达降低主要依赖于细胞周期蛋白D1蛋白降解的增加。此外,用SYT-SSX cDNA转染小鼠成纤维细胞可提高细胞周期蛋白D1的稳定性。因为用蛋白酶体抑制剂处理可恢复细胞周期蛋白D1的表达,所以似乎SYT-SSX干扰了细胞周期蛋白D1的泛素依赖性降解。然而,已证明SYT-SSX调节的细胞周期蛋白D1表达独立于糖原合成酶激酶-3β途径。综上所述,我们的研究提供了证据表明SYT-SSX可稳定细胞周期蛋白D1,并且对滑膜肉瘤细胞中细胞周期蛋白D1的表达至关重要。细胞周期蛋白D1的SYT-SSX依赖性表达可能是滑膜肉瘤发生和发展的重要机制,也为靶向治疗提供了可能性。

相似文献

1
SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation.SYT-SSX对滑膜肉瘤细胞中细胞周期蛋白D1的表达至关重要:t(X;18)(p11.2;q11.2)易位的功能获得。
Cancer Res. 2002 Jul 1;62(13):3861-7.
2
The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery.滑膜肉瘤的SYT-SSX1融合类型与细胞周期蛋白A和D1的表达增加有关。t(X;18)(p11.2; q11.2)与细胞周期机制之间的联系。
Oncogene. 2002 Aug 22;21(37):5791-6. doi: 10.1038/sj.onc.1205700.
3
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.SYT-SSX基因融合作为滑膜肉瘤形态和预后的决定因素
N Engl J Med. 1998 Jan 15;338(3):153-60. doi: 10.1056/NEJM199801153380303.
4
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.在人类滑膜肉瘤中发现的与t(X;18)(p11.2;q11.2)易位相关的新基因SYT和SSX的鉴定。
Nat Genet. 1994 Aug;7(4):502-8. doi: 10.1038/ng0894-502.
5
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.SYT-SSX融合类型对滑膜肉瘤临床行为的影响:一项针对243例患者的多机构回顾性研究
Cancer Res. 2002 Jan 1;62(1):135-40.
6
Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma.滑膜肉瘤中SYT-SSX融合类型与增殖活性及预后的关系
Mod Pathol. 2000 May;13(5):482-8. doi: 10.1038/modpathol.3880083.
7
The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex.滑膜肉瘤易位蛋白SYT-SSX2将β-连环蛋白募集到细胞核中,并在一个活性复合物中与其结合。
Oncogene. 2006 Jun 22;25(26):3661-9. doi: 10.1038/sj.onc.1209413. Epub 2006 Feb 6.
8
Fusions of the SYT and SSX genes in synovial sarcoma.滑膜肉瘤中SYT和SSX基因的融合
Oncogene. 2001 Sep 10;20(40):5755-62. doi: 10.1038/sj.onc.1204601.
9
Molecular diagnosis of synovial sarcoma: RT-PCR detection of SYT-SSX1/2 fusion transcripts in paraffin-embedded tissue.滑膜肉瘤的分子诊断:石蜡包埋组织中SYT-SSX1/2融合转录本的逆转录聚合酶链反应检测
Med Sci Monit. 2005 Mar;11(3):MT1-7.
10
Reverse transcription-polymerase chain reaction in situ hybridization for SYT-SSX fusion gene transcripts in synovial sarcomas.滑膜肉瘤中SYT-SSX融合基因转录本的逆转录聚合酶链反应原位杂交
Int J Mol Med. 2005 Oct;16(4):763-6.

引用本文的文献

1
DNA demethylating agents suppress preclinical models of synovial sarcoma.DNA去甲基化剂可抑制滑膜肉瘤的临床前模型。
J Clin Invest. 2025 Apr 29;135(13). doi: 10.1172/JCI190855. eCollection 2025 Jul 1.
2
Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells.含溴结构域和额外末端结构域抑制剂对滑膜肉瘤细胞的治疗潜力
Cancers (Basel). 2024 Mar 11;16(6):1125. doi: 10.3390/cancers16061125.
3
Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.
泛 PI3K 抑制剂处理后 PUMA 和 BIM 诱导易位相关性肉瘤细胞亚类选择性凋亡。
Cell Death Dis. 2023 Feb 27;14(2):169. doi: 10.1038/s41419-023-05690-7.
4
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research.滑膜肉瘤临床前建模:整合转基因小鼠模型和患者来源模型用于转化研究
Cancers (Basel). 2023 Jan 18;15(3):588. doi: 10.3390/cancers15030588.
5
Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma.建立并鉴定 NCC-SS5-C1:滑膜肉瘤的新型患者来源细胞系。
Hum Cell. 2022 Jul;35(4):1290-1297. doi: 10.1007/s13577-022-00721-5. Epub 2022 Jun 2.
6
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.组蛋白去乙酰化酶抑制剂通过上调 ERK-EGR1-乙酰肝素酶轴为滑膜肉瘤的合理治疗干预提供靶点。
J Exp Clin Cancer Res. 2021 Dec 2;40(1):381. doi: 10.1186/s13046-021-02150-y.
7
Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis.ARHI和Beclin1在甲状腺癌中的表达水平及其与临床病理和预后的关系。
Oncol Lett. 2020 Feb;19(2):1241-1246. doi: 10.3892/ol.2019.11223. Epub 2019 Dec 17.
8
Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma.IGF1/胰岛素受体过度激活和NRAS Q61R突变驱动滑膜肉瘤对帕唑帕尼的耐药机制并确定合理的联合治疗策略。
Cancers (Basel). 2019 Mar 22;11(3):408. doi: 10.3390/cancers11030408.
9
is negatively regulated by Kit in gastrointestinal stromal tumors.在胃肠道间质瘤中,其受到Kit的负调控。
Oncotarget. 2018 Jun 5;9(43):27016-27026. doi: 10.18632/oncotarget.25469.
10
Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells.表没食子儿茶素没食子酸酯和水飞蓟宾对软组织肉瘤细胞的抗增殖活性。
Mol Med Rep. 2017 Jan;15(1):103-110. doi: 10.3892/mmr.2016.5969. Epub 2016 Nov 28.